Please login to the form below

Not currently logged in
Email:
Password:

Opdivo

This page shows the latest Opdivo news and features for those working in and with pharma, biotech and healthcare.

Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma

Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma

Just last week NICE issued draft guidance not recommending Opdivo, saying the clinical and cost effectiveness data was not strong enough. ... BMS has had mixed success in gaining NICE approval for Opdivo across its many cancer indications.

Latest news

More from news
Approximately 122 fully matching, plus 159 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    It’s not all been plain sailing, with BMS’Opdivo (nivolumab) and Roche’s Tecentriq not doing as well as hoped in frontline NSCLC, revealing there are differences between checkpoint inhibitors – ... Opdivo after standard treatment of early-stage

  • The good, the bad and the ugly The good, the bad and the ugly

    Though its main competitor, BMS’Opdivo, was first to the NSCLC market, Merck’s frontline trial for Keytruda succeeded whereas Opdivo’s failed.

  • Accelerating innovation Accelerating innovation

    Leading this work is an agreement with Bristol-Myers Squibb to study a combination of Cabometyx and that firm’s blockbuster immuno-oncology drug Opdivo (nivolumab) and an agreement with Roche

  • Deal Watch September 2016 Deal Watch September 2016

    A clinical co-operation between Bristol-Myers Squibb and Nektar Therapeutics was closed under which Opdivo [nivolumab] will be evaluated in combination with Nektar's NKTR-214 in phase I/II

  • Deal Watch October 2015 Deal Watch October 2015

    Acquisition - company. 2, 300. Five Prime Therapeutics/ Bristol-Myers Squibb. CSF1R antibody programme, incl FPA008 (p1) in immunology/ oncology in combination with Opdivo/ other therapies.

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

  • BMS appoints CCO, Stephen Davies joins Eisai and more BMS appoints CCO, Stephen Davies joins Eisai and more

    The move comes at a challenging time for BMS, as its blockbuster immunotherapy Opdivo has just been overtaken in global revenues by its arch-rival, Merck &Co's Keytruda. ... BMS looks unlikely to take the lead again, but Boerner can ensure Opdivo remains

  • BMS appoints oncology development head BMS appoints oncology development head

    On moving to the US in 2006, Dr Namouni took over responsibility for metastatic colorectal cancer treatment Erbitux (cetuximab), before serving as development lead for Opdivo (nivolumab) and Yervoy (ipilimumab).

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • A stumble, but not a fall – what’s next for Opdivo?

    Bristol-Myers Squibb's (BMS, $BMY) immunotherapy wonder drug  Opdivo (nivolumab) was poised for lasting success. ... Some chinks in the Opdivo armor were evident back in June 2016, but were largely overlooked.

  • Video: Immuno-oncology therapies

    However, these therapies come with a very high price tag and currently only a few of these drugs have actually reached the market including Opdivo, Keytruda and Yervoy.

  • Video: Immuno-oncology therapies

    However, these therapies come with a very high price tag and currently only a few of these drugs have actually reached the market including Opdivo, Keytruda and Yervoy.

  • ASCO 2015: What you missed in Chicago

    Bristol-Myers-Squibb redefines Melanoma treatment standards. In terms of winners here, BMS is likely to redefine the standard of care in Melanoma with the Opdivo/Yervoy (ipilimumab) combination. ... challenge Opdivo will depend on how the European

  • Blue Latitude Health

    A stumble, but not a fall – what’ s next for Opdivo?. ... Blue Latitude Health's Louis Perdios talks about the daunting challenges faced by BMS after Opdivo's disappointing results.

More from PMHub
Approximately 1 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics